Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. (RLAY) reported that Donald A. Bergstrom, President, R&D, sold 8,530 shares of common stock on September 8, 2026 in an open-market or private transaction at a weighted average price of $18.97 per share, under a Rule 10b5-1 trading plan adopted on October 30, 2025. After this sale, he directly holds 399,130 shares, including 10,025 shares underlying restricted stock units.
Relay Therapeutics, Inc. (RLAY) reports that Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock on September 8, 2026 at a weighted average price of $18.94 per share in a sale in the open market or a private transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025 and was executed in multiple trades at prices ranging from $18.34 to $19.25. Following this transaction, Catinazzo beneficially owns 122,851 shares, including 6,538 shares underlying restricted stock units, held directly.
Relay Therapeutics, Inc. (RLAY) President and CEO Sanjiv Patel reported a sale of 48,199 shares of common stock on September 8, 2026 at a weighted average price of $18.94 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.
After this sale, he holds 519,500 shares directly and additional shares indirectly through family irrevocable trusts, for which he disclaims beneficial ownership.
Relay Therapeutics, Inc. (RLAY) reported that Chief Corporate Development Officer Peter Rahmer sold 4,508 sharesRule 10b5-1 trading plan$20.03 per share223,657 shares6,102 shares underlying restricted stock units
Relay Therapeutics, Inc. (RLAY) reported that entities associated with SoftBank sold 6,000,000 shares of its Common Stock on August 25, 2026, in a sale classified as an open market or private transaction at $19.40 per share. The shares are held of record by SVF Pauling (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P., with SB Investment Advisers (UK) Limited acting as alternative investment fund manager and exclusively responsible for acquisition, financing, voting and disposal decisions. Following this transaction, the reporting structure indicates 21,904,963 shares of Relay Therapeutics Common Stock remain held indirectly by these entities.
Relay Therapeutics, Inc. (RLAY) reports that officer Peter Rahmer has filed a Rule 144 notice to sell up to 50,000 shares of common stock through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $1,028,500, with an approximate sale date of 08/26/2026 on NASDAQ. The shares relate to Restricted Stock Units granted on 01/28/2025 by the issuer. Relay Therapeutics states that 219,141,631 shares of common stock are outstanding. The filing also notes prior 10b5-1 plan sales of 50,000 shares for $954,560 on 06/30/2026.
Relay Therapeutics, Inc. (symbol RLAY) received a Rule 144 notice relating to a proposed sale of its common stock by stockholder SVF Pauling (Cayman) Ltd. The notice covers up to 6,000,000 shares of common stock to be sold through Citigroup Global Markets Inc. on NASDAQ, with a stated aggregate market value of $123,420,000.00. Shares of Relay Therapeutics common stock outstanding were 219,141,631 as of the date referenced in the notice; this is a baseline figure, not the amount being offered. The securities to be sold were originally acquired upon the automatic conversion of Series C Convertible Preferred Stock in connection with Relay Therapeutics’ initial public offering, with the shares fully paid for in December 2018. The proposed sale date referenced is August 25, 2026.
Relay Therapeutics, Inc. (RLAY) reported that President and CEO Sanjiv Patel sold 48,199 shares of common stock on August 17, 2026 in an open-market transaction at a weighted average price of $20.33 per share, effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025. Following this sale, he directly held 567,699 shares of common stock. Additional shares totaling 199,548 and 687,355 are held in separate irrevocable trusts for the benefit of his family members, with an independent trustee; Patel disclaims beneficial ownership of those trust-held securities.
Relay Therapeutics, Inc. (RLAY) reported that its Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of common stock on August 14, 2026 in an open-market transaction at a weighted average price of $19.74 per share, under a previously adopted Rule 10b5-1 trading plan. After this sale, he directly holds 140,568 shares of Relay Therapeutics common stock, which include 6,538 shares underlying restricted stock units.
Relay Therapeutics, Inc. has a significant shareholder group led by Commodore Capital LP, which, together with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, reports beneficial ownership of 12,000,000 shares of common stock. As of June 30, 2026, this represents 5.5% of the outstanding common stock, based on 218,531,200 shares reported as issued and outstanding. The group reports no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over the full 12,000,000 shares. Commodore Capital LP serves as investment manager to Commodore Capital Master LP, and Atkinson and Kramarz, as managing partners, exercise investment discretion with respect to these securities.